|Articles|October 1, 2016
- Pharmaceutical Executive-10-01-2016
- Volume 36
- Issue 10
Pharmaceutical Executive, October 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive October 2016 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 10 years ago
Content Marketing’s Data Fail: Information Without Insight?almost 10 years ago
The Rise of the CFO Strategist: Balancing Numbers and Know-howalmost 10 years ago
Steps Toward Rare Disease Successalmost 10 years ago
‘Huge Sellers’ Herald Changes in Japan Drug Pricingalmost 10 years ago
Real-World Evidence: From Volume to Valuealmost 10 years ago
Pharma and the Peril of Europe’s Trade Policiesalmost 10 years ago
New Challenge to IP Innovationalmost 10 years ago
Major Changes Ahead for Drug User Feesalmost 10 years ago
Country Report: Czech RepublicAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Significance of FDA’s First Warning Letter for Inappropriate Use of AI
2
Jazz Pharmaceuticals to Acquire Actio Biosciences for $1.32 Billion
3
M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo
4
Generating Commercial Evidence from Agentic Field and Brand Engagement to Accelerate Launch Performance
5